Literature DB >> 6976301

Acute type B hepatitis among HBsAg negative patients detected by anti-HBc IgM.

P Kryger, J Aldershvile, L R Mathiesen, J O Nielsen.   

Abstract

A consecutive group of 169 patients with acute hepatitis found negative for hepatitis B surface antigen (HBsAg) and negative for IgM antibody against hepatitis A (anti-HAV IgM) was studied for presence of IgM antibody against hepatitis B core antigen (anti-HBc IgM) by ELISA. Anti-HBc IgM was found in a total of 34 of 60 patients with detectable total anti-HBc. One hundred and nine patients had no detectable anti-HBc IgM and no total anti-HBc and were thus considered as having acute non-A, non-B hepatitis. Among the 34 patients with anti-HBc IgM in their first serum sample, 23 were anti-HBs negative and all had high and steadily decreasing ratio unit (RU) values for anti-HBc IgM (mean RU value 17.1). Twelve of the 23 patients showed seroconversion to anti-HBs during the follow-up, indicating an actual hepatitis B virus infection. Eleven of the 34 anti-HBc IgM positive patients had anti-HBs in their first serum sample. In this group, the RU values for anti-HBc IgM were high and steadily declining and the initial values were significantly lower (mean RU value 9.9) (p less than 0.05) than in the anti-HBs negative group. Evidence is provided that anti-HBc IgM in serum from patients with HBsAg negative hepatitis with or without anti-HBs indicates an actual hepatitis B virus infection. According to generally accepted criteria, the demonstration of anti-HBc IgM identified 20% of the 169 patients with acute non-A, non-B hepatitis as having an actual hepatitis B infection.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6976301     DOI: 10.1002/hep.1840020108

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  10 in total

1.  Radioimmunoassays of hidden viral antigens.

Authors:  A R Neurath; N Strick; L Baker; S Krugman
Journal:  Proc Natl Acad Sci U S A       Date:  1982-07       Impact factor: 11.205

2.  Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs.

Authors:  Jing Tan; Jingguo Zhou; Pan Zhao; Jing Wei
Journal:  Clin Rheumatol       Date:  2012-04-28       Impact factor: 2.980

3.  Absence of circulating HBsAg in acute hepatitis B.

Authors:  J Fasel-Felley; R Peitrequin; P C Frei
Journal:  Infection       Date:  1984 May-Jun       Impact factor: 3.553

4.  Hepatitis virus non-A, non-B: the cause of a major public health problem in India.

Authors:  B N Tandon; B M Gandhi; Y K Joshi; M Irshad; H Gupta
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408

5.  [Anti-HBc IgM in acute and chronic hepatitis B virus infection].

Authors:  K Gmelin; L Theilmann; G Hasche; H Will; P Czygan; H W Doerr; B Kommerell
Journal:  Klin Wochenschr       Date:  1984-09-03

6.  Use of hepatitis B core antigen produced in Escherichia coli to detect immunoglobulin M specific antibodies in an enzyme-linked immunosorbent assay.

Authors:  G Hasche; J Stecher; K Gmelin; H W Doerr
Journal:  Eur J Clin Microbiol       Date:  1984-02       Impact factor: 3.267

7.  A possible misdiagnosis in patients presenting with acute HBsAg-negative hepatitis: the role of hepatitis delta virus.

Authors:  F Caredda; S Antinori; C Pastecchia; P Coppin; C Arici; O Fracassetti
Journal:  Infection       Date:  1988       Impact factor: 3.553

8.  Serological diagnosis of acute viral hepatitis.

Authors:  J H Hoofnagle; A Ponzetto; L R Mathiesen; J G Waggoner; Z B Bales; L B Seeff
Journal:  Dig Dis Sci       Date:  1985-11       Impact factor: 3.199

9.  Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease.

Authors:  Quan Yuan; Liu-Wei Song; Daniela Cavallone; Francesco Moriconi; Beatrice Cherubini; Piero Colombatto; Filippo Oliveri; Barbara Agata Coco; Gabriele Ricco; Ferruccio Bonino; James Wai Kuo Shih; Ning-Shao Xia; Maurizia Rossana Brunetto
Journal:  PLoS One       Date:  2015-06-26       Impact factor: 3.240

10.  Quantitative anti-HBc combined with quantitative HBsAg can predict HBsAg clearance in sequential combination therapy with PEG-IFN-α in NA-suppressed chronic hepatitis B patients.

Authors:  Wen-Xin Wang; Rui Jia; Ying-Ying Gao; Jia-Ye Liu; Jun-Qing Luan; Fei Qiao; Li-Min Liu; Xiao-Ning Zhang; Fu-Sheng Wang; Junliang Fu
Journal:  Front Immunol       Date:  2022-07-26       Impact factor: 8.786

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.